EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2
Chelation got a surprise win in the first TACT trial. Airborne lead levels are now much lower, potentially explaining today’s loss.
Chelation got a surprise win in the first TACT trial. Airborne lead levels are now much lower, potentially explaining today’s loss.
Music, tour dates, videos and more from Young the Giant.
Objectives Although controversial, recent data suggest nighttime versus daytime laparoscopic cholecystectomy (LC) have comparable outcomes. Laparoscopic common bile duct exploration (LCBDE) for choledocholithiasis decreases length…
Mayo Clinic researchers have developed a new scoring tool that links Alzheimer’s disease subtypes with age of onset and the […]
Ischemic heart disease (IHD) is the leading cause of morbidity and mortality in both genders; however, young women fare the worst, likely reflecting the more…
There remains an unmet need for therapies proven to lower the increased CV risk seen in this population.
Compared with patients who fasted, those who didn’t reported a better overall experience with zero safety compromises.
Interventionalists say it’s now time to make a dent in the complication rate, whether by strict protocols or smaller devices.
Going forward, data from these kinds of studies could increasingly be used by AI to help personalize therapy for HF patients, an editorial suggests.
Left Ventricular Assist Devices buy precious time for patients on heart transplant waiting lists.
Jagmeet Singh joins Harriette Van Spall to discuss artificial intelligence in the realm of heart failure.